Belpointe Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Belpointe Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-366	Closed	-$3.85K	–	2358
2023 Q1	$3.85K	Hold	366	–	–	﹤0.01%	3108
2022 Q4	$12.4K	Buy	+366	New	+$17.7K	﹤0.01%	2496
2019 Q2	–	Sell	-198	Closed	-$100K	–	636
2019 Q1	$100K	Buy	+198	New	+$117K	0.02%	449
2018 Q4	–	Sell	-134	Closed	-$123K	–	589
2018 Q3	$123K	Buy	+134	New	+$114K	0.02%	588
2018 Q2	–	Sell	-132	Closed	-$210K	–	374
2018 Q1	$210K	Buy	+132	New	+$170K	0.06%	305

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Belpointe Asset Management's NKTR Position: Q2 2023 in Review

Belpointe Asset Management sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 366 shares — an estimated $3.85K sold.

Belpointe Asset Management first reported a position in NKTR in Q1 2018 and held it in 5 quarters. The position peaked at $210K in Q1 2018. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

Belpointe Asset Management reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 366 Nektar Therapeutics shares in Q2 2023, an estimated $3.85K.
Belpointe Asset Management first reported a position in Nektar Therapeutics in Q1 2018 and held it in 5 quarters.
Belpointe Asset Management's Nektar Therapeutics position peaked at $210K in Q1 2018.
146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.